S100A16 promotes metastasis and progression of pancreatic cancer through FGF19-mediated AKT and ERK1/2 pathways.

Cell Line, Tumor Cell Movement Cell Proliferation / genetics Fibroblast Growth Factors Gene Expression Regulation, Neoplastic Humans MAP Kinase Signaling System Pancreatic Neoplasms / genetics Proto-Oncogene Proteins c-akt / genetics S100 Proteins / genetics
AKT ERK1/2 Metastasis Pancreatic cancer S100A16

Journal

Cell biology and toxicology
ISSN: 1573-6822
Titre abrégé: Cell Biol Toxicol
Pays: Switzerland
ID NLM: 8506639

Informations de publication

Date de publication:
08 2021
Historique:
received: 07 07 2020
accepted: 17 11 2020
pubmed: 4 1 2021
medline: 14 1 2022
entrez: 3 1 2021
Statut: ppublish

Résumé

The S100 protein family genes play a crucial role in multiple stages of tumorigenesis and progression. Most of S100 genes are located at chromosome locus 1q21, which is a region frequently rearranged in cancers. Here, we examined the expression of the S100 family genes in paired pancreatic ductal adenocarcinoma (PDAC) samples and further validated the expression of S100A16 by immunohistochemistry staining. We found that S100A16 is significantly upregulated in clinical PDAC samples. However, its roles in PDAC are still unclear. We next demonstrated that S100A16 promotes PDAC cell proliferation, migration, invasion, and metastasis both in vitro and in vivo. Knockdown of S100A16 induces PDAC cell cycle arrest in the G2/M phase and apoptosis. Furthermore, we also demonstrated that S100A16 promotes PDAC cell proliferation, migration, and invasion via AKT and ERK1/2 signaling in a fibroblast growth factor 19 (FGF19)-dependent manner. Taken together, our results reveal that S100A16 is overexpressed in PDAC and promotes PDAC progression through FGF19-mediated AKT and ERK1/2 signaling, suggesting that S100A16 may be a promising therapeutic target for PDAC. S100A16 was upregulated in PDAC and associated with prognosis of PDAC patients. S100A16 regulates apoptosis and the cell cycle of pancreatic cancer cells. S100A16 promotes the progression of pancreatic cancer by AKT-ERK1/2 signaling. S100A16 may be a promising therapeutic target for PDAC.

Identifiants

DOI: 10.1007/s10565-020-09574-w PMID: 33389337
pubmed: 33389337
doi: 10.1007/s10565-020-09574-w
pii: 10.1007/s10565-020-09574-w
doi:

Substances chimiques

FGF19 protein, human 0
S100 Proteins 0
S100A16 protein, human 0
Fibroblast Growth Factors 62031-54-3
Proto-Oncogene Proteins c-akt EC 2.7.11.1

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

555-571

Informations de copyright

© 2021. Springer Nature B.V.

Références

Babini E, Bertini I, Borsi V, Calderone V, Hu X, Luchinat C, et al. Structural characterization of human S100A16, a low-affinity calcium binder. J Biol Inorg Chem: JBIC: a Publ Soc Biol Inorg Chem. 2011;16(2):243–56. https://doi.org/10.1007/s00775-010-0721-3 .
doi: 10.1007/s00775-010-0721-3
Cao Z, Liao Q, Su M, Huang K, Jin J, Cao D. AKT and ERK dual inhibitors: the way forward? Cancer Lett. 2019;459:30–40. https://doi.org/10.1016/j.canlet.2019.05.025 .
doi: 10.1016/j.canlet.2019.05.025 pubmed: 31128213
Chen LL, Liang C. Aberrant S100A16 expression might be an independent prognostic indicator of unfavorable survival in non-small cell lung adenocarcinoma. PloS ONE. 2018;13(5):e0197402. https://doi.org/10.1371/journal.pone.0197402 .
doi: 10.1371/journal.pone.0197402 pubmed: 29746588 pmcid: 5945035
Dhillon AS, Hagan S, Rath O, Kolch W. MAP kinase signalling pathways in cancer. Oncogene. 2007;26(22):3279–90. https://doi.org/10.1038/sj.onc.1210421 .
doi: 10.1038/sj.onc.1210421 pubmed: 17496922
Ding L, Madamsetty VS, Kiers S, Alekhina O, Ugolkov A, Dube J et al. Glycogen synthase kinase-3 inhibition sensitizes pancreatic cancer cells to chemotherapy by abrogating the TopBP1/ATR-mediated DNA damage response. Clin Cancer Res. 2019;25(21):6452–62. https://doi.org/10.1158/1078-0432.CCR-19-0799 .
Fang C, Guo X, Lv X, Yin R, Lv X, Wang F, et al. Dysbindin promotes progression of pancreatic ductal adenocarcinoma via direct activation of PI3K. J Mol Cell Biol. 2017;9(6):504–15. https://doi.org/10.1093/jmcb/mjx043 .
doi: 10.1093/jmcb/mjx043 pubmed: 29040676 pmcid: 6283123
Gao L, Lang L, Zhao X, Shay C, Shull AY, Teng Y. FGF19 amplification reveals an oncogenic dependency upon autocrine FGF19/FGFR4 signaling in head and neck squamous cell carcinoma. Oncogene. 2019;38(13):2394–404. https://doi.org/10.1038/s41388-018-0591-7 .
doi: 10.1038/s41388-018-0591-7 pubmed: 30518874
Garcia MN, Grasso D, Lopez-Millan MB, Hamidi T, Loncle C, Tomasini R, et al. IER3 supports KRASG12D-dependent pancreatic cancer development by sustaining ERK1/2 phosphorylation. J Clin Invest. 2014;124(11):4709–22. https://doi.org/10.1172/jci76037 .
doi: 10.1172/jci76037 pubmed: 25250570 pmcid: 4347237
Gillen S, Schuster T, Meyer Zum Buschenfelde C, Friess H, Kleeff J. Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLoS Med. 2010;7(4):e1000267. https://doi.org/10.1371/journal.pmed.1000267 .
doi: 10.1371/journal.pmed.1000267 pubmed: 20422030 pmcid: 2857873
Halbrook CJ, Lyssiotis CA. Employing metabolism to improve the diagnosis and treatment of pancreatic cancer. Cancer Cell. 2017;31(1):5–19. https://doi.org/10.1016/j.ccell.2016.12.006 .
doi: 10.1016/j.ccell.2016.12.006 pubmed: 28073003
Hessmann E, Johnsen SA, Siveke JT, Ellenrieder V. Epigenetic treatment of pancreatic cancer: is there a therapeutic perspective on the horizon? Gut. 2017;66(1):168–79. https://doi.org/10.1136/gutjnl-2016-312539 .
doi: 10.1136/gutjnl-2016-312539 pubmed: 27811314
Hu J, Li L, Chen H, Zhang G, Liu H, Kong R, et al. MiR-361-3p regulates ERK1/2-induced EMT via DUSP2 mRNA degradation in pancreatic ductal adenocarcinoma. Cell Death Dis. 2018;9(8):807. https://doi.org/10.1038/s41419-018-0839-8 .
doi: 10.1038/s41419-018-0839-8 pubmed: 30042387 pmcid: 6057920
Iodice S, Gandini S, Maisonneuve P, Lowenfels AB. Tobacco and the risk of pancreatic cancer: a review and meta-analysis. Langenbeck's Arch Surg. 2008;393(4):535–45. https://doi.org/10.1007/s00423-007-0266-2 .
doi: 10.1007/s00423-007-0266-2
Jokinen E, Koivunen JP. MEK and PI3K inhibition in solid tumors: rationale and evidence to date. Ther Adv Med Oncol. 2015;7(3):170–80. https://doi.org/10.1177/1758834015571111 .
doi: 10.1177/1758834015571111 pubmed: 26673580 pmcid: 4406912
Kirkegard J, Cronin-Fenton D, Heide-Jorgensen U, Mortensen FV. Acute pancreatitis and pancreatic cancer risk: a nationwide matched-cohort study in Denmark. Gastroenterology. 2018;154(6):1729–36. https://doi.org/10.1053/j.gastro.2018.02.011 .
doi: 10.1053/j.gastro.2018.02.011 pubmed: 29432727
Kumarasamy V, Ruiz A, Nambiar R, Witkiewicz AK, Knudsen ES. Chemotherapy impacts on the cellular response to CDK4/6 inhibition: distinct mechanisms of interaction and efficacy in models of pancreatic cancer. Oncogene. 2019;39:1831–45. https://doi.org/10.1038/s41388-019-1102-1 .
doi: 10.1038/s41388-019-1102-1 pubmed: 31745297 pmcid: 7047578
Law HC, Lagundzin D, Clement EJ, Qiao F, Wagner ZS, Krieger KL et al. The proteomic landscape of pancreatic ductal adenocarcinoma liver metastases identifies molecular subtypes and associations with clinical response. Clin Cancer Res. 2020;26(5):1065-76. https://doi.org/10.1158/1078-0432.CCR-19-1496
Liu Y, Cao M, Cai Y, Li X, Zhao C, Cui R. Dissecting the role of the FGF19-FGFR4 signaling pathway in cancer development and progression. Front Cell Dev Biol. 2020;8:95.
doi: 10.3389/fcell.2020.00095
Luo J, Manning BD, Cantley LC. Targeting the PI3K-Akt pathway in human cancer: rationale and promise. Cancer Cell. 2003;4(4):257–62. https://doi.org/10.1016/s1535-6108(03)00248-4 .
doi: 10.1016/s1535-6108(03)00248-4 pubmed: 14585353
Maisonneuve P, Lowenfels AB. Risk factors for pancreatic cancer: a summary review of meta-analytical studies. Int J Epidemiol. 2015;44(1):186–98. https://doi.org/10.1093/ije/dyu240 .
doi: 10.1093/ije/dyu240 pubmed: 25502106
Manji GA, Olive KP, Saenger YM, Oberstein P. Current and emerging therapies in metastatic pancreatic cancer. Clin Cancer Res: Off J Am Assoc Cancer Res. 2017;23(7):1670–8. https://doi.org/10.1158/1078-0432.ccr-16-2319 .
doi: 10.1158/1078-0432.ccr-16-2319
Marenholz I, Heizmann CW. S100A16, a ubiquitously expressed EF-hand protein which is up-regulated in tumors. Biochem Biophys Res Commun. 2004;313(2):237–44. https://doi.org/10.1016/j.bbrc.2003.11.115 .
doi: 10.1016/j.bbrc.2003.11.115 pubmed: 14684152
Nevala-Plagemann C, Hidalgo M, Garrido-Laguna I. From state-of-the-art treatments to novel therapies for advanced-stage pancreatic cancer. Nat Rev Clin Oncol. 2019;17:108–23. https://doi.org/10.1038/s41571-019-0281-6 .
doi: 10.1038/s41571-019-0281-6 pubmed: 31705130
Pang Y, Holmes MV, Chen Z, Kartsonaki C. A review of lifestyle, metabolic risk factors, and blood-based biomarkers for early diagnosis of pancreatic ductal adenocarcinoma. J Gastroenterol Hepatol. 2019;34(2):330–45. https://doi.org/10.1111/jgh.14576 .
doi: 10.1111/jgh.14576 pubmed: 30550622 pmcid: 6378598
Raja A, Park I, Haq F, Ahn SM. FGF19-FGFR4 signaling in hepatocellular carcinoma. Cells. 2019;8(6):536. https://doi.org/10.3390/cells8060536 .
Riquelme E, Behrens C, Lin HY, Simon G, Papadimitrakopoulou V, Izzo J, et al. Modulation of EZH2 expression by MEK-ERK or PI3K-AKT signaling in lung cancer is dictated by different KRAS oncogene mutations. Cancer Res. 2016;76(3):675–85. https://doi.org/10.1158/0008-5472.can-15-1141 .
doi: 10.1158/0008-5472.can-15-1141 pubmed: 26676756
Riquelme E, Zhang Y, Zhang L, Montiel M, Zoltan M, Dong W, et al. Tumor microbiome diversity and composition influence pancreatic cancer outcomes. Cell. 2019;178(4):795–806.e12. https://doi.org/10.1016/j.cell.2019.07.008 .
doi: 10.1016/j.cell.2019.07.008 pubmed: 31398337 pmcid: 7288240
Sturchler E, Cox JA, Durussel I, Weibel M, Heizmann CW. S100A16, a novel calcium-binding protein of the EF-hand superfamily. J Biol Chem. 2006;281(50):38905–17. https://doi.org/10.1074/jbc.M605798200 .
doi: 10.1074/jbc.M605798200 pubmed: 17030513
Sun X, Wang T, Zhang C, Ning K, Guan ZR, Chen SX et al. S100A16 is a prognostic marker for colorectal cancer. 2018;117(2):275–83. https://doi.org/10.1002/jso.24822 .
Testa JR, Bellacosa A. AKT plays a central role in tumorigenesis. Proc Natl Acad Sci U S A. 2001;98(20):10983–5. https://doi.org/10.1073/pnas.211430998 .
doi: 10.1073/pnas.211430998 pubmed: 11572954 pmcid: 58668
Tomiyama N, Ikeda R, Nishizawa Y, Masuda S, Tajitsu Y, Takeda Y. S100A16 up-regulates Oct4 and Nanog expression in cancer stem-like cells of Yumoto human cervical carcinoma cells. Oncol Lett. 2018;15(6):9929–33. https://doi.org/10.3892/ol.2018.8568 .
doi: 10.3892/ol.2018.8568 pubmed: 29928366 pmcid: 6004699
Tramacere I, Scotti L, Jenab M, Bagnardi V, Bellocco R, Rota M, et al. Alcohol drinking and pancreatic cancer risk: a meta-analysis of the dose-risk relation. Int J Cancer. 2010;126(6):1474–86. https://doi.org/10.1002/ijc.24936 .
doi: 10.1002/ijc.24936 pubmed: 19816941
Wang K, Ji W, Yu Y, Li Z, Niu X, Xia W. FGFR1-ERK1/2-SOX2 axis promotes cell proliferation, epithelial-mesenchymal transition, and metastasis in FGFR1-amplified lung cancer. Oncogene. 2018;37(39):5340–54. https://doi.org/10.1038/s41388-018-0311-3 .
doi: 10.1038/s41388-018-0311-3 pubmed: 29858603
Yamamoto S, Tomita Y, Hoshida Y, Morooka T, Nagano H, Dono K, et al. Prognostic significance of activated Akt expression in pancreatic ductal adenocarcinoma. Clin Cancer Res: Off J Am Assoc Cancer Res. 2004;10(8):2846–50. https://doi.org/10.1158/1078-0432.ccr-02-1441 .
doi: 10.1158/1078-0432.ccr-02-1441
Yoo YA, Kang MH, Lee HJ, Kim BH, Park JK, Kim HK, et al. Sonic hedgehog pathway promotes metastasis and lymphangiogenesis via activation of Akt, EMT, and MMP-9 pathway in gastric cancer. Cancer Res. 2011;71(22):7061–70. https://doi.org/10.1158/0008-5472.can-11-1338 .
doi: 10.1158/0008-5472.can-11-1338 pubmed: 21975935
Zhu W, Xue Y, Liang C, Zhang R, Zhang Z, Li H, et al. S100A16 promotes cell proliferation and metastasis via AKT and ERK cell signaling pathways in human prostate cancer. Tumour Biol: J Int Soc Oncodev Biol Med. 2016;37(9):12241–50. https://doi.org/10.1007/s13277-016-5096-9 .
doi: 10.1007/s13277-016-5096-9

Auteurs

Dan Fang (D)

Department of Pathology, School of Basic Medical Sciences & Sir Run Run Hospital & State Key Laboratory of Reproductive Medicine & Key Laboratory of Antibody Technique of National Health Commission, Nanjing Medical University, Nanjing, 211166, China.

Chengfei Zhang (C)

Department of Pathology, School of Basic Medical Sciences & Sir Run Run Hospital & State Key Laboratory of Reproductive Medicine & Key Laboratory of Antibody Technique of National Health Commission, Nanjing Medical University, Nanjing, 211166, China.

Ping Xu (P)

Department of Pathology, School of Basic Medical Sciences & Sir Run Run Hospital & State Key Laboratory of Reproductive Medicine & Key Laboratory of Antibody Technique of National Health Commission, Nanjing Medical University, Nanjing, 211166, China.

Yinhua Liu (Y)

Department of Pathology, The First Affiliated Yijishan Hospital of Wannan Medical College & Key Laboratory of Non-coding RNA Transformation Research of Anhui Higher Education Institutes, Wannan Medical College, Wuhu, 241002, China.

Xiao Mo (X)

Department of Pathology, School of Basic Medical Sciences & Sir Run Run Hospital & State Key Laboratory of Reproductive Medicine & Key Laboratory of Antibody Technique of National Health Commission, Nanjing Medical University, Nanjing, 211166, China.

Qi Sun (Q)

Department of Pathology, School of Basic Medical Sciences & Sir Run Run Hospital & State Key Laboratory of Reproductive Medicine & Key Laboratory of Antibody Technique of National Health Commission, Nanjing Medical University, Nanjing, 211166, China.

Alaa Abdelatty (A)

Department of Pathology, School of Basic Medical Sciences & Sir Run Run Hospital & State Key Laboratory of Reproductive Medicine & Key Laboratory of Antibody Technique of National Health Commission, Nanjing Medical University, Nanjing, 211166, China.
Key Laboratory of Diagnosis and Treatment of Severe Hepato-Pancreatic Diseases of Zhejiang Province, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, 325000, China.

Chao Hu (C)

Department of Pathology, School of Basic Medical Sciences & Sir Run Run Hospital & State Key Laboratory of Reproductive Medicine & Key Laboratory of Antibody Technique of National Health Commission, Nanjing Medical University, Nanjing, 211166, China.

Haojun Xu (H)

Department of Pathology, School of Basic Medical Sciences & Sir Run Run Hospital & State Key Laboratory of Reproductive Medicine & Key Laboratory of Antibody Technique of National Health Commission, Nanjing Medical University, Nanjing, 211166, China.

Guoren Zhou (G)

Jiangsu Cancer Hospital, The Affiliated Cancer Hospital of Nanjing Medical University, Jiangsu Institute of Cancer Research, 2100092, Nanjing, China. zhouguoren888@126.com.

Hongping Xia (H)

Department of Pathology, School of Basic Medical Sciences & Sir Run Run Hospital & State Key Laboratory of Reproductive Medicine & Key Laboratory of Antibody Technique of National Health Commission, Nanjing Medical University, Nanjing, 211166, China. xiahongping@njmu.edu.cn.
Department of Pathology, The First Affiliated Yijishan Hospital of Wannan Medical College & Key Laboratory of Non-coding RNA Transformation Research of Anhui Higher Education Institutes, Wannan Medical College, Wuhu, 241002, China. xiahongping@njmu.edu.cn.
Jiangsu Cancer Hospital, The Affiliated Cancer Hospital of Nanjing Medical University, Jiangsu Institute of Cancer Research, 2100092, Nanjing, China. xiahongping@njmu.edu.cn.
Key Laboratory of Diagnosis and Treatment of Severe Hepato-Pancreatic Diseases of Zhejiang Province, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, 325000, China. xiahongping@njmu.edu.cn.
ORCID: 0000-0001-6454-2333

Linhua Lan (L)

Key Laboratory of Diagnosis and Treatment of Severe Hepato-Pancreatic Diseases of Zhejiang Province, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, 325000, China. paullee90@wmu.edu.cn.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Cellules › Cellules cultivées › Cellules cancéreuses en culture › Lignée cellulaire tumorale › S100A16 promotes metastasis and progression of...
questionsmedicales.fr › Phénomènes physiologiques › Mouvement cellulaire › S100A16 promotes metastasis and progression of...
questionsmedicales.fr › Phénomènes physiologiques › Croissance et développement › Croissance › Processus de croissance cellulaire › Prolifération cellulaire › S100A16 promotes metastasis and progression of...
questionsmedicales.fr › Facteurs biologiques › Protéines et peptides de signalisation intercellulaire › Facteurs de croissance fibroblastique › S100A16 promotes metastasis and progression of...
questionsmedicales.fr › Phénomènes génétiques › Régulation de l'expression des gènes › Régulation de l'expression des gènes tumoraux › S100A16 promotes metastasis and progression of...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › S100A16 promotes metastasis and progression of...
questionsmedicales.fr › Phénomènes physiologiques cellulaires › Transduction du signal › Système de signalisation des MAP kinases › S100A16 promotes metastasis and progression of...
questionsmedicales.fr › Maladies endocriniennes › Tumeurs des glandes endocrines › Tumeurs du pancréas › S100A16 promotes metastasis and progression of...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines tumorales › Protéines oncogènes › Protéines proto-oncogènes › Protéines proto-oncogènes c-akt › S100A16 promotes metastasis and progression of...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines de tissu nerveux › Protéines S100 › S100A16 promotes metastasis and progression of...